All Clinical Trials

A listing of 23136 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

NCT03958565

Recruiting

The purpose of this study is to assess percentage reduction in the of urine NTX and serum CTX , in patients with NSCLC and bone metastases 1) with actionable driver oncogene on standard of care (SOC) TKI at 3 months post treatment and 2) without actionable mutations on standard of care therapy (chemotherapy/immunotherapy) treated with zoledronic acid or denosumab at the same time period.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

05/15/2025

Locations: University of Colorado Hospital, Aurora, Colorado +1 locations

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997

Recruiting

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Local Institution - 035, Hot Springs, Arkansas +278 locations

Local Institution - 035, Hot Springs, Arkansas

The Oncology Institute Of Hope And Innovation, Cerritos, California

Local Institution - 683, Corona, California

Los Angeles Cancer Network - Fountain Valley, Fountain Valley, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

USC Norris Comprehensive Cancer Center, Newport, California

Yale University School Of Medicine, New Haven, Connecticut

Local Institution - 029, Fort Myers, Florida

Local Institution - 049, Jacksonville, Florida

Ocala Oncology Center, Ocala, Florida

Local Institution - 028, Saint Petersburg, Florida

BRCR Global, Tamarac, Florida

Local Institution - 034, West Palm Beach, Florida

Cleveland Clinic Florida, Weston, Florida

Emory University School of Medicine, Atlanta, Georgia

Alexian Brothers Hospital Network, Elk Grove Village, Illinois

Local Institution - 689, Urbana, Illinois

Northwest Cancer Center, Dyer, Indiana

Norton Cancer Institute - St. Matthews Campus, Louisville, Kentucky

Local Institution - 041, Alexandria, Louisiana

Our Lady of the Lake Cancer Institute, Baton Rouge, Louisiana

Local Institution - 027, Baton Rouge, Louisiana

Local Institution - 696, New Orleans, Louisiana

Greater Baltimore Medical Center, Baltimore, Maryland

Center For Cancer And Blood Disorders, Bethesda, Maryland

Maryland Oncology Hematology (Columbia) - USOR, Columbia, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts

Minnesota Oncology Hematology, P.A. - Burnsville, Burnsville, Minnesota

Local Institution - 694, Kansas City, Missouri

HCA Midwest Health, Kansas City, Missouri

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings, Montana

Local Institution - 015, Summit, New Jersey

Local Institution - 042, Bay Shore, New York

Manhattan Hematology Oncology Center, New York, New York

Duke University Hospital, Durham, North Carolina

TriHealth, Good Samaritan Hospital, Cincinnati, Ohio

Local Institution - 644, Cincinnati, Ohio

Local Institution - 037, Cleveland, Ohio

Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio

Ohio Health Corporation, Columbus, Ohio

Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma

Oregon Health and Science University, Portland, Oregon

Local Institution - 048, Hershey, Pennsylvania

Tennessee Oncology, Chattanooga, Tennessee

Tennessee Oncology - Nashville, Nashville, Tennessee

Texas Oncology-Austin Midtown, Austin, Texas

Kelsey Seybold Clinic Berthelsen Main Campus, Houston, Texas

Local Institution - 690, Houston, Texas

USOR - Virginia Oncology Associates - Newport News, Newport News, Virginia

Blue Ridge Cancer Care, Roanoke, Virginia

Local Institution - 646, Vancouver, Washington

University Of Wisconsin, Madison, Wisconsin

Local Institution - 080, Ciudad Autanoma De Buenos Aires, Buenos Aires

Local Institution - 083, Villa Elisa, Buenos Aires

Local Institution - 813, Birtinya, Queensland

Local Institution - 812, Douglas, Queensland

Local Institution - 803, Adelaide, South Australia

Local Institution - 806, Bedford Park, South Australia

Local Institution - 802, Clayton, Victoria

Local Institution - 809, East Melbourne, Victoria

Local Institution - 801, Melbourne, Victoria

Local Institution - 811, Murdoch, Western Australia

Local Institution - 807, West Perth, Western Australia

Local Institution - 804, Camperdown, Not set

Local Institution - 800, Fitzroy, Not set

Local Institution - 808, Garran, Not set

Local Institution - 155, Graz, Not set

Local Institution - 154, Linz, Not set

Local Institution - 153, Salzburg, Not set

Local Institution - 156, St Polten, Not set

Local Institution - 150, Vienna, Not set

Local Institution - 151, Wien, Not set

Local Institution - 157, Wien, Not set

Local Institution - 172, Brugge, Not set

Local Institution - 174, Bruxelles, Not set

Local Institution - 056, Curitiba, Parana

Local Institution - 058, Porto Alegre, RIO Grande DO SUL

Local Institution - 050, Porto Alegre, RS

Local Institution - 054, Jau, SAO Paulo

Local Institution - 055, Sao Paulo, SP

Local Institution - 051, Barretos, São Paulo

Local Institution - 053, Rio de Janeiro, Not set

Local Institution - 057, Sao Paulo, Not set

Local Institution - 052, Sao Paulo, Not set

Local Institution - 111, Calgary, Alberta

Local Institution - 103, Edmonton, Alberta

Local Institution - 112, Surrey, British Columbia

Local Institution - 104, Saint John, New Brunswick

Local Institution - 110, St John's, Newfoundland and Labrador

Local Institution - 101, Halifax, Nova Scotia

Local Institution - 109, Ottawa, Quebec

Local Institution - 107, Saskatoon, Saskatchewan

Local Institution - 108, Quebec, Not set

Local Institution - 141, Changsha, Hunan

Local Institution - 129, Nanchang, Jiangxi

Local Institution - 143, Xian, Shaanxi

Local Institution - 142, Shanghai, Shanghai

Local Institution - 145, Taiyuan, Shanxi

Local Institution - 144, Wenzhou, Zhejiang

Local Institution - 140, Beijing, Not set

Local Institution - 139, Beijing, Not set

Local Institution - 138, Beijing, Not set

Local Institution - 126, Changchun, Not set

Local Institution - 121, Chaoyang District, Not set

Local Institution - 135, Guangzhou, Not set

Local Institution - 136, Guangzhou, Not set

Local Institution - 128, Hangzhou City, Not set

Local Institution - 120, Hangzhou, Zhejiang, Not set

Local Institution - 127, Harbin, Not set

Local Institution - 134, Nanjing, Not set

Local Institution - 132, Shanghai, Not set

Local Institution - 130, Shanghai, Not set

Local Institution - 131, Shenyang, Not set

Local Institution - 124, Suzhu, Not set

Local Institution - 133, Tianjin, Not set

Local Institution - 137, Wuhan, Not set

Local Institution - 125, Xian, Not set

Local Institution - 123, Zhengzhou, Not set

Local Institution - 601, Brno, Not set

Local Institution - 600, Ostrava-Poruba, Not set

Local Institution - 602, Prague 2, Not set

Local Institution - 371, Aalborg, Not set

Local Institution - 370, Odense, Not set

Local Institution - 372, Roskilde, Not set

Local Institution - 231, Turku, Varsinais-Suomi

Local Institution - 230, Helsinki, Not set

Local Institution - 232, Oulu, Not set

Local Institution - 463, Argenteuil, Not set

Local Institution - 462, La Roche -Sur-Yon - Cedex 9, Not set

Local Institution - 451, Lille Cedex, Not set

Local Institution - 458, Nancy Cedex, Not set

Local Institution - 454, Nantes, Not set

Local Institution - 452, Paris Cedex, Not set

Local Institution - 456, Paris, Not set

Local Institution - 464, Pessac, Not set

Local Institution - 465, Rouen, Not set

Local Institution - 457, Toulouse Cedex 9, Not set

Local Institution - 308, Kiel, Schleswig-Holstein

Local Institution - 301, Frankfurt am Main, Not set

Local Institution - 300, Hamburg, Not set

Local Institution - 302, Hamburg, Not set

Local Institution - 305, Heidelberg, Not set

Local Institution - 304, Lubeck, Not set

Local Institution - 573, Patras, Achaea

Local Institution - 574, Patra, Achaia

Local Institution - 571, Athens, Not set

Local Institution - 572, Thessaloniki, Not set

Local Institution - 570, Thessaloniki, Not set

Local Institution - 932, Hyderabad, Andhra Pradesh

Local Institution - 930, Bangalore, Karnataka

Local Institution - 934, Ernakulam, Kerala

Local Institution - 933, Mumbai, Maharashtra

Local Institution - 935, Kolkata, West Bengal

Local Institution - 931, Pondicherry, Not set

Local Institution - 752, Cork, Not set

Local Institution - 750, Dublin 9, Not set

Local Institution - 751, Galway, Not set

Local Institution - 874, Afula, HaZafon

Local Institution - 872, Haifa, Not set

Local Institution - 871, Jerusalem, Not set

Local Institution - 870, Tel Aviv, Not set

Local Institution - 873, Tel Hashomer, Not set

Local Institution - 415, Roma, Lazio

Local Institution - 400, Bologna, Not set

Local Institution - 408, Catania, Not set

Local Institution - 414, Genova, Not set

Local Institution - 404, Milano, Not set

Local Institution - 407, Milano, Not set

Local Institution - 410, Novara, Not set

Local Institution - 412, Pavia, Not set

Local Institution - 402, Pisa, Not set

Local Institution - 405, Reggio Calabria, Not set

Local Institution - 413, Reggio Emilia, Not set

Local Institution - 401, Roma, Not set

Local Institution - 403, San Giovanni Rotondo FG, Not set

Local Institution - 409, Terni, Not set

Local Institution - 406, Udine, Not set

Local Institution - 900, Matsuyama, Ehime

Local Institution - 917, Higashi-Ibaraki-gun, Ibaraki

Local Institution - 919, Shimotsuga, Tochigi

Local Institution - 920, Nerima-ku, Tokyo

Local Institution - 918, Shinagawa-ku, Tokyo

Local Institution - 915, Chuo-shi, Yamanashi

Local Institution - 912, Aomori, Not set

Local Institution - 916, Chiba, Not set

Local Institution - 911, Fukuoka, Not set

Local Institution - 903, Kamogawa, Not set

Local Institution - 902, Kyoto-City, Not set

Local Institution - 910, Nagoya, Not set

Local Institution - 901, Nagoya, Not set

Local Institution - 905, Okayama, Not set

Local Institution - 908, Osaka-Sayama, Not set

Local Institution - 907, Osaka, Not set

Local Institution - 913, Sapporo, Not set

Local Institution - 914, Sendai, Not set

Local Institution - 906, Shibuya-ku, Not set

Local Institution - 909, Shinagawa-ku, Tokyo, Not set

Local Institution - 904, Toyohashi, Not set

Local Institution - 974, Daegu, Not set

Local Institution - 973, Gyeonggi-do, Not set

Local Institution - 975, Hwasun-gun, Not set

Local Institution - 971, Seoul, Not set

Local Institution - 976, Seoul, Not set

Local Institution - 972, Seoul, Not set

Local Institution - 970, Seoul, Not set

Local Institution - 977, Seoul, Not set

Local Institution - 182, Mexico City, Distrito Federal

Local Institution - 183, Guadalajara, Jalisco

Local Institution - 181, La Raza, Not set

Local Institution - 180, Mexico City, Not set

Local Institution - 351, Dordrecht, Zuid-Holland

Local Institution - 354, Amsterdam, Not set

Local Institution - 352, Den Haag, Not set

Local Institution - 202, Bergen, Not set

Local Institution - 200, Oslo, Not set

Local Institution - 201, Trondheim, Not set

Local Institution - 631, Bialystok, Podlaskie

Local Institution - 633, Krakow, Not set

Local Institution - 635, Nowy Sacz, Not set

Local Institution - 634, Poznan, Not set

Local Institution - 636, Walbrzych, Not set

Local Institution - 630, Warszawa, Not set

Local Institution - 545, Coimbra, Not set

Local Institution - 543, Lisboa, Not set

Local Institution - 544, Lisboa, Not set

Local Institution - 540, Porto, Not set

Local Institution - 541, Porto, Not set

Local Institution - 791, Pretoria, Gauteng

Local Institution - 790, Cape Town, Western Cape

Local Institution - 792, Kuils River, Western Cape

Local Institution - 514, Pamplona, Navarra

Local Institution - 505, Barcelona, Not set

Local Institution - 502, Barcelona, Not set

Local Institution - 511, Barcelona, Not set

Local Institution - 501, Caceres, Not set

Local Institution - 509, Cordoba, Not set

Local Institution - 510, Madrid, Not set

Local Institution - 516, Madrid, Not set

Local Institution - 504, Madrid, Not set

Local Institution - 513, Madrid, Not set

Local Institution - 503, Malaga, Not set

Local Institution - 508, Murcia, Not set

Local Institution - 506, Oviedo, Not set

Local Institution - 515, Salamanca, Not set

Local Institution - 500, Santiago de Compostela, Not set

Local Institution - 512, Valencia, Not set

Local Institution - 507, Zaragoza, Not set

Local Institution - 272, Boras, Not set

Local Institution - 271, Helsingborg, Not set

Local Institution - 851, Chur, Not set

Local Institution - 850, St. Gallen, Not set

Local Institution - 955, Niao-Sung Hsiang Kaohsiung County, Not set

Local Institution - 952, Taichung City, Not set

Local Institution - 954, Taichung, Not set

Local Institution - 951, Tainan, Taiana, Not set

Local Institution - 956, Taipei, Zhongzheng Dist., Not set

Local Institution - 950, Taipei, Not set

Local Institution - 953, Taoyuan City, Not set

Local Institution - 778, Kavaklıdere, Ankara

Local Institution - 776, Yenimahalle, Ankara

Local Institution - 777, Pendik, Istanbul

Local Institution - 771, Balçova, Izmir

Local Institution - 775, Bornova, Izmir

Local Institution - 773, Samsun, Kurupelit

Local Institution - 770, Ankara, Not set

Local Institution - 772, Gaziantep, Not set

Local Institution - 774, Kayseri, Not set

Local Institution - 702, Nottingham, Nottinghamshire

Local Institution - 705, Belfast Northern Ireland, Not set

Local Institution - 700, Birmingham, Not set

Local Institution - 707, Canterbury Kent, Not set

Local Institution - 704, Lancashire Blackpool, Not set

Local Institution - 701, London, Not set

Local Institution - 709, London, Not set

Local Institution - 706, Oxford, Not set

Local Institution - 711, Portsmouth, Not set

Local Institution - 713, Sutton, Not set

Local Institution - 708, Wolverhampton, Not set

Conditions: Multiple Myeloma

Learn More ›

Preoperative Irradiation for Stage I Breast Cancer

NCT05464667

Recruiting

The novel use of preoperative RT will have broad implications for breast cancer patients, most of whom present with early-stage disease. In the era of reduced chemotherapy delivery, preoperative RT will allow oncologists to assess radiologic and biologic tumor response and correlate it to outcomes. Underutilization of RT negatively affects mortality. This trial aims to further evaluate pre-operative radiation therapy in patients with early stage, biologically favorable breast cancer, with improv... Read More

Gender:

FEMALE

Ages:

50 years and above

Trial Updated:

05/15/2025

Locations: UPMC Magee Womens Hospital - Radiation Oncology, Pittsburgh, Pennsylvania

Conditions: Breast Cancer

Learn More ›

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

NCT05691010

Recruiting

The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey +6 locations

Conditions: Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma, Endometrial Carcinoma Stage III

Learn More ›

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

NCT06058988

Recruiting

The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

Conditions: Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma

Learn More ›

Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women

NCT06337708

Recruiting

The purpose of this study is to test a culturally tailored, smartphone-delivered intervention designed to increase physical activity and reduce risk for heart disease and type 2 diabetes among African American women.

Gender:

FEMALE

Ages:

Between 24 years and 65 years

Trial Updated:

05/15/2025

Locations: Arizona State University, Phoenix, Arizona

Conditions: Physical Activity, Exercise, Heart Diseases, Diabetes Mellitus, Physical Inactivity

Learn More ›

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

NCT06607627

Recruiting

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

Gender:

ALL

Ages:

Between 6 years and 17 years

Trial Updated:

05/15/2025

Locations: Research Site, Washington, District of Columbia +11 locations

Conditions: Generalized Myasthenia Gravis, gMG

Learn More ›

ZTE MRI Pulse Sequence Use for Visualization of Bone Cement, Breast Biopsy Markers

NCT06873802

Recruiting

This study is being done to determine if a clinically available MRI sequence called ZTE imaging better visualizes breast biopsy markers made of bone cement compared to the currently used breast biopsy markers made of metal.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Breast Carcinoma

Learn More ›

Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

NCT03958747

Recruiting

This pilot clinical trial studies how well ultrasound works in detecting oxaliplatin-induced neuropathy in patients with gastrointestinal cancer. Ultrasound may work better in diagnosing and detecting neuropathy in gastrointestinal cancer patients treated with the chemotherapy drug called a oxaliplatin.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

Conditions: Gastrointestinal Cancer, Colorectal Cancer

Learn More ›

EUS-RFA PANCARDINAL-1 Trial

NCT04990609

Recruiting

The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Memorial Hermann Hospital, Houston, Texas

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)

Learn More ›

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

NCT05474378

Recruiting

This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Stanford Cancer Institute, Palo Alto, California

Conditions: Brain and Nervous System

Learn More ›

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

NCT05698524

Recruiting

Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standard therapy, radiation therapy and chemotherapy with temozolomide, few options are available. Even with further therapy, median progression free survival at 6 months after first relapse (PFS-6) is only... Read More

Gender:

ALL

Ages:

19 years and above

Trial Updated:

05/15/2025

Locations: University of Nebraska Medical Center, Omaha, Nebraska

Conditions: Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma

Learn More ›